Peter Blume-Jensen is a corporate insider at Acrivon Therapeutics, Inc. (ACRV). Blume-Jensen has reported 14 insider filings with the SEC since 2024. The most recent filing was in May 2026.
Every role Peter Blume-Jensen has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Acrivon Therapeutics, Inc. (ACRV)2 filingsUpdated Aug 30, 2026
Peter Blume-Jensen is President and CEO, Director of Acrivon Therapeutics, Inc. (ACRV). 16 SEC Form 4 filings on record going back to 2024, most recently on 27 August 2026. Most recent open-market trade: sold $31K of ACRV on 27 August 2026. Lifetime open-market purchases: $82K. Lifetime open-market sales: $34K.
Every recent SEC Form 4 transaction Peter Blume-Jensen has reported, most recent first.
InsiderAlpha's records for Peter Blume-Jensen go back to 2024: 16 primary Form 4 filings, an average of 5.3 per year. The typical open-market purchase is $82K (1 buy totaling $82K). The largest single buy on record is $82K of ACRV in 2026. Sales side: 3 recorded sales totaling $34K, so the filing history runs buy-heavy by dollar value. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Insiders who reported open-market trades in the last 12 months at the companies Peter Blume-Jensen files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Peter Blume-Jensen is a corporate insider, tracked as President and CEO, Director of Acrivon Therapeutics, Inc. (ACRV). InsiderAlpha holds 16 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchase ($82K) and 3 open-market sales ($34K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$ACRV Acrivon Therapeutics, Inc.1.2K shares @ $2.01$2K